Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer

NCT04983095 is registered in ClinicalTrials.gov with Karin Soderkvist as lead sponsor.

NCT NCT04983095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04983095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer
Lead sponsor
Karin Soderkvist
Phase
Not applicable
Overall status
Recruiting
Start date
October 27, 2021
Completion date
December 31, 2033
Enrollment
118 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

positron-emission tomography, prostate cancer metastatic, radiation therapy